指南与共识血栓与止血

ASH ISTH NHF WFH 2021 血管性血友病诊断指南

ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.
指南 / 共识 · Blood Adv · 2021-01-01

该指南由 ASH、ISTH、NHF 和 WFH 联合制定,采用 GRADE 方法,基于截至 2020 年 1 月 8 日的系统证据综述,针对血管性血友病(VWD)诊断提出 11 条推荐,涵盖出血评估工具、1 型和 2 型 VWD 的实验室检测与 cutoff、1 型患者水平正常化后的处理以及 2B 和 2N 型的基因检测与表型检测选择。

要点

  • 推荐使用出血评估工具评估疑似 VWD 患者。
  • 明确 1 型和 2 型 VWD 的诊断检测与实验室 cutoff。
  • 2B 和 2N 型应权衡基因检测与表型检测。

核心结论

  • 指南就 VWD 诊断达成 11 条推荐,覆盖出血评估、分型检测及基因检测应用。

研究设计与样本

  • ASH、ISTH、NHF 和 WFH 组建多学科指南小组,含 4 名患者代表,由 KUMC 支持系统证据综述更新至 2020 年 1 月 8 日,采用 GRADE 方法形成推荐并公开征求意见。

主要发现

  • 指南小组就 11 条推荐达成共识,涉及出血评估工具、1 型和 2 型 VWD 的诊断检测与实验室 cutoff、1 型患者水平正常化后的处理以及 2B 和 2N 型的基因检测与表型检测选择。

关键数值与推荐

  • 推荐条款包括出血评估工具在疑似 VWD 评估中的作用、1 型和 2 型 VWD 的诊断检测与实验室 cutoff、1 型 VWD 患者水平正常化后的处理策略以及 2B 和 2N 型基因检测与表型检测的角色。

临床怎么用

  • 临床医生可依据 11 条推荐规范 VWD 的诊断流程,包括出血评估、分型检测及基因检测的合理应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: von Willebrand disease (VWD) is the most common inherited bleeding disorder known in humans. Accurate and timely diagnosis presents numerous challenges. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and other health care professionals in their decisions about VWD diagnosis. METHODS: ASH, ISTH, NHF, and WFH established a multidisciplinary guideline panel that included 4 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Outcomes and Implementation Research Unit at the University of Kansas Medical Center (KUMC) supported the guideline-development process, including performing or updating systematic evidence reviews up to 8 January 2020. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently subject to public comment. RESULTS: The panel agreed on 11 recommendations. CONCLUSIONS: Key recommendations of these guidelines include the role of bleeding-assessment tools in the assessment of patients suspected of VWD, diagnostic assays and laboratory cutoffs for type 1 and type 2 VWD, how to approach a type 1 VWD patient with normalized levels over time, and the role of genetic testing vs phenotypic assays for types 2B and 2N. Future critical research priorities are also identified.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021. PMID: 33570651. doi:10.1182/bloodadvances.2020003265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。